Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers
ObjectiveThe myosin-binding protein C (MYBPC3) c.927-2A>G founder mutation accounts for >90% of sarcomeric hypertrophic cardiomyopathy (HCM) in Iceland. This cross-sectional observational study explored the penetrance and phenotypic burden among carriers of this single, prevalent founder mutat...
Na minha lista:
| Principais autores: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2020-06-01
|
| Serier: | Open Heart |
| Online adgang: | https://openheart.bmj.com/content/7/1/e001220.full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
